Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 Mar;35(3):328-9.
doi: 10.1086/675350.

Reply to Tan et al

David T Kuhar  1 , Kimberly A Struble, David K Henderson
Affiliations
Comment

Reply to Tan et al

David T Kuhar et al. Infect Control Hosp Epidemiol. 2014 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. All authors report no conflicts of interest relevant to this article. All authors submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest, and the conflicts that the editors consider relevant to this article are disclosed here.

Comment on

References

    1. Tan DHS, Goddey-Erikefe B, Yoong D, et al. Selecting an anti-retroviral regimen for human immunodeficiency virus postexposure prophylaxis in the occupational setting. Infect Control Hosp Epidemiol. 2013;35:326–328. - PubMed
    1. Kuhar DT, Henderson DK, Struble KA, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol. 2013;34:875–892. - PubMed
    1. Mayer KH, Mimiaga MJ, Gelman M, Grasso C. Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. J Acquir Immune Defic Syndr. 2012;59:354–359. - PubMed
    1. McAllister J, Read P, McNulty A, Tong W, Ingersoll A, Carr A. Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence. HIV Med. 2014;15:13–22. - PubMed
    1. Tosini W, Muller P, Prazuck T, et al. Tolerability of HIV post-exposure prophylaxis with tenofovir/emtricitabine and lopinivir/ritonavir tablet formation. AIDS. 2010;24:2375–2380. - PubMed